GeoVax Labs (NASDAQ:GOVX) Issues Earnings Results

GeoVax Labs (NASDAQ:GOVX) released its quarterly earnings data on Tuesday. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38, Zacks reports. The company had revenue of $2.79 million for the quarter, compared to analyst estimates of $1.84 million. During the same period in the previous year, the business posted ($4.80) EPS.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $2.59 on Thursday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The business’s 50-day moving average price is $2.42 and its 200 day moving average price is $2.59.

Analysts Set New Price Targets

GOVX has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Monday, August 12th. Alliance Global Partners initiated coverage on GeoVax Labs in a research report on Monday. They set a “buy” rating and a $15.00 target price on the stock. Noble Financial boosted their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. Finally, EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $13.25.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.